Volume | 97,998 |
|
|||||
News | - | ||||||
Day High | 8.44 | Low High |
|||||
Day Low | 7.81 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Solid Biosciences Inc | SLDB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
8.31 | 7.81 | 8.44 | 7.90 | 8.51 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,105 | 97,998 | US$ 8.08 | US$ 791,574 | - | 1.81 - 15.05 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:37:10 | formt | 100 | US$ 7.95 | USD |
Solid Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
298.28M | 37.76M | - | 0 | -96.02M | -2.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Solid Biosciences News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLDB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.59 | 8.71 | 7.40 | 7.96 | 236,446 | 0.36 | 4.74% |
1 Month | 9.17 | 9.243 | 7.16 | 8.08 | 204,656 | -1.22 | -13.30% |
3 Months | 13.39 | 15.05 | 7.16 | 10.10 | 213,336 | -5.44 | -40.63% |
6 Months | 4.44 | 15.05 | 4.33 | 9.11 | 271,523 | 3.51 | 79.05% |
1 Year | 6.19 | 15.05 | 1.81 | 6.64 | 263,991 | 1.76 | 28.43% |
3 Years | 61.95 | 62.775 | 1.81 | 22.32 | 514,114 | -54.00 | -87.17% |
5 Years | 78.90 | 203.70 | 1.81 | 54.14 | 838,873 | -70.95 | -89.92% |
Solid Biosciences Description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of speciality and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |